National UK guidelines for the management of paediatric craniopharyngioma.
Journal
The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
20
03
2023
revised:
25
05
2023
accepted:
01
06
2023
medline:
28
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic-pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour and the tumour itself can cause pronounced long-term neuroendocrine morbidity against a background of high overall survival. To date, the optimal management strategy for these tumours remains undefined, with practice varying between centres. In light of these discrepancies, as part of a national endeavour to create evidence-based and consensus-based guidance for the management of rare paediatric endocrine tumours in the UK, we aimed to develop guidelines, which are presented in this Review. These guidelines were developed under the auspices of the UK Children's Cancer and Leukaemia Group and the British Society for Paediatric Endocrinology and Diabetes, with the oversight and endorsement of the Royal College of Paediatrics and Child Health using Appraisal of Guidelines for Research & Evaluation II methodology to standardise care for children and young people with craniopharyngiomas.
Identifiants
pubmed: 37549682
pii: S2213-8587(23)00162-6
doi: 10.1016/S2213-8587(23)00162-6
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
694-706Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests H-WG received a one-off consulting fee from Rhythm Pharmaceuticals for development of a drug for hypothalamic obesity (not listed in manuscript, and not licensed for this indication currently). BZ has received honoraria from Medtronic for delivering lectures on electromagnetic neuronavigation and equipment and financial support to run the annual International Endoscopy in Neurosurgery course. HAS is the voluntary chair and founder of the SUCCESS Charity. All other authors declare no competing interests.